In this preclinical model, CD4+ and CD8+ T cells mediate immune control over EBV infection and B-cell lymphoma development and protective EBV-specific CD4+ T cells can be primed with vaccine candidates [33–35]. The gene discussed is CD4; the disease is B-cell non-Hodgkin lymphoma.